Finally, there is some hope for triple-negative breast cancer patients, a hitherto essentially untreatable and aggressive form of breast cancer. A new treatment, consisting of standard weekly chemotherapy and immunotherapy medication atezolizumab, which is given once every two weeks. The chemotherapy changes the appearance of the cell membrane of cancer cells (it is getting rougher), which can then be attacked by the body’s own immune system, as it recognizes the cancer cells as foreign objects. This combinational therapy prolongs the life of patients by ten months, and reduces the risk of cancer progressing by up to 40 per cent. The new therapy is currently under review by health authorities.

Read the full story: Queen Mary University of London
Scientific publication: New England Journal of Medicine